Ir direto para menu de acessibilidade.

Banner MosquitoNao 960x100px

Você está aqui: Página inicial > CTIS2017 > English > Rodas de conversa
Início do conteúdo da página

Rodas de conversa

Publicado: Segunda, 27 de Novembro de 2017, 11h01
November 29






1 – 1:30 pm

Human Cells of induced pluripotency (iPS)  for drug screening and toxicity testing
Antonio Carlos Campos de Carvalho
(National Network of Cellular Therapy)

Magnetic medicine
Fabiano Paixão

New biomarker for detection of hepatic steatosis based on clinical-laboratory characteristics of the multicenter ELSA-Brazil study
Hugo Perazzo

Strategies for genetic research of individuals with Autism Spectrum Disorder (ASD) by the Public Health System in Goiás
Thaís Cidália Gigonzac

Process management and clinical research
Emerson Lima Aredes

1:30 – 2 pm

The use of iPS due cells in clinical trials for response and non-response to medications selection
Lygia Pereira
(National Network of Cellular Therapy)

Technological innovation in diagnosis and rehabilitation
Guilherme Fregonezi

Molecular diagnosis and artificial intelligence as a solution to a public health problem: 40 thousand unnecessary thyroid surgeries per year in Brazil
Marcos Tadeu dos Santos
(ONKOS Diagnósticos Moleculares LTDA)

Molecular diagnosis of X-Fragile Syndrome: perspectives for the public health system in the central region of Brazil
Marc Alexandre Gigonzac

SANI system as a form of mobilization of financial resources
Marlan Geronimo

2 – 2:30 pm

The Cellular Technology Centers of the National Network of Cellular Therapy
Mari Sogayar
(National Network of Cellular Therapy)


Evidence-based regulatory performance: scientific-technical support structure of ANVISA
Danitza Buvinich

Microparticulate implants for single-dose treatment of chronic diseases such as Leishmaniasis
Bartira Rossi Bergmann
(LeishNano e UFRJ)

Non-invasive brain stimulation in the control of drug use in chemical dependency
Ester Nakamura

Pharmaceutical Market Regulation Chamber (CMED)
Leandro Safatle


November 30







1 – 1:30 pm

Support and supply of stem cells in GMP conditions for use in clinical and therapeutic trials

Paulo Roberto Slud Brofman

Development and evaluation of an auxiliary mobile telephone application for high-risk pregnant women
Antonia Iracilda e Silva Viana

The Innovation Hub of the IFBA and the EMBRAPII financing model
Handerson Jorge Dourado Leite

Turning poison into medicine
Rui Seabra Ferreira Junior

RAMBO – Anatomy Morpho-biological recognition
Ricardo Abdalla

Recent advances by the National Research Commission - Conep
Pedro Canisio Binsfeld
(Executive Secretariat of CONEP)

1:30 – 2 pm

Ways to scientific partnerships and research development with the pharmaceutical industry: GSK Experiences
Luciana Tarbes Mattana Saturnino

Use of technology to promote integration in Health Surveillance in monitoring pregnant women infected with arboviruses
Ariadne Barbosa

Open Innovation - Johnson & Johnson Model
Ricardo Tolentino
(Janssen Farmacêutica)

Biotechnological products of marine origin
Fabiano Thompson

Technologies to meet the limitations of cervical cancer screening in Brazil
Ramon Salinas


2 – 2:30 pm

Advanced Therapy Products’s Regulation
João Batista da Silva Junior

REDPB - Use of mobile technology to collect data on people with disabilities
Silvana Santos

Clinical Research with Medicines: Regulatory Issues amidst Globalization
Flávia Sobral

Marine biotechnology and biomedical innovation - new marine sources of potent anti-metastatics
Mauro Sergio Pavão

Current scenario and perspectives after Joint Ordinance 01/2017, INPI and Anvisa
Liane Elizabeth Caldeira Lage (INPI)



November 29 - Room Acácia
Antonio Carlos Campos de Carvalho (Rede Nacional de Terapia Celular)
Title: Human Cells of induced pluripotency (iPS)  for drug screening and toxicity testing.
Abstract: It will presented the characteristics of iPS and the possibilities of its use in disease modeling, drug selection and toxicity tests. As they are carried out in human cells it offers advantages over the use of animals. We will explore the concept of a body in a "chip" for the substitution of animal experimentation in drug tests.

Lygia Pereira (Rede Nacional de Terapia Celular)
Title: The use of iPS due cells in clinical trials for response and non-response to medications selection.
Abstract: It will be discussed the use of differentiated cells from induced pluripotency cells (iPS) in clinical trials for selection of genetic characteristics of patients responding to or not responding to a particular drug. These clinical trials, which can be categorized as phase 0.5 trials, allow a considerable saving of resources to pharmaceutical companies, since they allow the prior selection of patients sensitive to the drugs tested.

Mari Sogayar (Rede Nacional de Terapia Celular)
Title: The Cellular Technology Centers of the National Network of Cellular Therapy
Abstract: It will be presented the Cell Technology Centers funded by DECIT of the Ministry of Health, presenting their capacity in the generation of stem cells of different types under conditions of good practices of manufacturing for use in clinical trials. It will also be presented the capacity of Laboratories associated with the National Network of Cell Therapy to develop pre-clinical trials in animal or cellular models of interest to the pharmaceutical industry

November 29 - Room Aroeira
Fabiano Paixão (UNIFESP)
Title: Magnetic medicine
Abstract: Currently, the set of technologies used to diagnose diseases of the gastrointestinal tract in humans is composed of Scintigraphy (Nuclear Medicine), Contrast X-rays, Videoscopy or Manometry. All of these methods have the drawback of using ionizing radiation or being invasive. In scientific research in gastroenterology, the methods employed necessarily involve the sacrifice of the animal for the taking of a single experimental data. Thus, current methods require a high number of guinea pigs for each experiment (high cost) and prevent the same animal from being used in different situations (control group, affected by disease or under the effect of medications). Magnetic Medicine is a technology, free of ionizing radiation and non-invasive, capable of making about 50% of the diagnoses of Nuclear Medicine in the area of ​​gastroenterology and the same scientific studies in animals without the need to sacrifice them, as it happens with the current methods. These facts make the technique extremely attractive commercially, both for medical diagnosis and for use in scientific research in gastroenterology.

Guilherme Fregonezi (UFRN)
Title: Technological innovation in diagnosis and rehabilitation
Abstract: Brazil occupies an insignificant place in the innovation aspect, related to the Industrial Health Complex, when considering its territorial and economic proportion. Therefore, both the reflection on this issue, as well as the efforts related to the technological development within the scope of the Industrial Health are appropriate and the objective of our laboratory is focused on the development of products related to technological innovation in health with a focus on Diagnosis and Rehabilitation. All of the projects being developed are related to the solutions of health problems, specifically, mechanical and electronic devices. These projects involve the development of technologies at the national level and involve intra-institutional partnerships at UFRN, PneumoCardioVascular Lab with the Neuro-engineering Laboratory and the Laboratory of Applied Molecular Biology, associated to other private partners within the scope of the Industrial Health Complex. Among those, there is the MOVAR Respiratory Airway Monitoring System that monitors various respiratory parameters in critical patients in intensive care units (ICU) or semi-intensive care units that are performed precariously. Currently, clinical parameters are used in the attempt of ventilatory weaning (removal of ventilator or artificial ventilation), which in many cases is insufficient and ineffective. The NeuroHolter - NH system, system for diagnoses and studies of Electroencephalogram (EEG) in a continuous and dynamic way; o Incentivator resso-Volumetric, a portable device designed to improve ventilation for patients admitted with chronic respiratory restrictive diseases and / or submitted to interventions such as thoracic surgery. Lastly, the Freemove-Functional Electrostimulator, an orthosis designed to improve gait functionality in children and adults with plantar fall due to diseases that affect the upper motor neuron, causing the drag of the foot on the ground during the march.

Danitza Rojas Buvinich (ANVISA)
Title: Evidence-based regulatory performance: ANVISA’s scientific-technical support Framework  
Abstract: The National Sanitary Surveillance Agency (Anvisa), created by Law 9,782 of January 26, 1999, has as its mission to protect the health of the population through intervention in sectors of sanitary interest to reduce risks arising from production and the use of products and services directly or indirectly linked to people's health. Its regulatory focus is very broad and complex, since it deals with access to essential goods and services and sanitary control in several sectors of the economy, which cover a significant part of the Brazilian Gross Domestic Product (GDP) and the daily lives of millions of people, not only in Brazil, but also in countries with which we maintain international relations. To carry out and promote studies and research within the scope of its competence is also the legal attribution of ANVISA and constitutes one of its institutional values. In this sense, the production of knowledge is carried out in a dialectical way as a means and end of the actions of sanitary surveillance, insofar as it seeks to provide the necessary support to the activities of regulation, monitoring and inspection of goods, products and services subject to sanitary surveillance and to control the problems related to them, generating new knowledge and practices. Such production enables an anticipated and prospective action in relation to scientific and technological development, to promote the protection of the health of the population in an environment favorable to the economic and social development of the country.
In this sense, the General Management of Knowledge, Innovation and Research is responsible for mobilizing and managing the necessary technical and scientific support structure so that the technical performance of the agency is the most qualified, updated and specialized available, so as to strengthen technical capacity for the evaluation of products and services subject to health surveillance. This Roda de Conversa aims to present to the participants the various technical-scientific support strategies used by ANVISA, as well as some results obtained in the process of promoting research in health surveillance.

November 29th - Room Buriti

Hugo Perazzo (FIOCRUZ - RJ)
Title: New biomarker for detection of hepatic steatosis based on clinical-laboratory characteristics of the multicentric research ELSA-Brazil.
Abstract: Introduction: Biomarkers validated in international populations are used for the diagnosis of hepatic steatosis in Brazil. Objective: To propose a new biomarker for the detection of hepatic steatosis parameterized in the Brazilian population. Methods: Cross-sectional study using data from the Longitudinal Study of Adult Health (ELSA-Brazil). Subjects were randomly assigned to the exploratory (n = 6,571) and confirmatory (n = 3,286) cohorts and steatosis was determined by abdominal ultrasonography. Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and NAFLD Liver Fat Score (NAFLD-LFS) were calculated and multivariate logistic regression was performed for the development of the new biomarker (Steato-ELSA). Results: 9,857 individuals [58% female, age = 51 (IQR, 45-58) years, body mass index (BMI) = 26.4 (23.9-29.6) kg / m2] were included. BMI, abdominal circumference, transaminases and triglycerides were independently associated with the presence of steatosis in the multivariate model (Hosmer-Lemeshow; p = 0.279). The areas under ROC curve (AUROCs [95% CI]) for prediction of mild / moderate steatosis were: Steato-ELSA = 0.768 [0.751-0.784] / 0.829 [0.810-0.848]; FLI = 0.762 [0.745-0.779] / 0.819 [0.799-0.838]; HSI = 0.743 [0.727-0.761] / 0.800 [0.779-0.822] and NAFLD-LFS = 0.719 [0.701-0.737] / 0.769 [0.747-0.791]. Steato-ELSA Sensitivity (Se) / Specificity (Sp) [95% CI] were: (i) mild steatosis (score≥0.386): Se = 65.6% [63.0-68.3] and Sp = 73 , 7% [71.8-75.6]; (ii) moderate steatosis (score≥0.403): Se = 83.5% [80.0-86.9] and Sp = 68.7% [67.0-70.4]. Conclusions: Steato-ELSA is a simple and accurate tool for the identification of hepatic steatosis developed in Brazilian subjects.

Marcos Tadeu dos Santos (ONKOS Diagnósticos Moleculares LTDA)
Title: Molecular diagnosis and artificial intelligence as a solution to a public health problem: 40 thousand unnecessary thyroid surgeries per year in Brazil
Abstract: Approximately 40,000 thyroidectomy surgeries are performed annually in Brazil unnecessarily due to the low sensitivity of current diagnostic tools that are unable to identify benignity or malignancy in up to 30% of thyroid nodules. This overtreatment generates a serious public health problem that impacts not only the quality of life of the patients but also one in about R $ 0.5 billion to the health system. We will present the results of mir-THYpe, a disruptive health technology developed in Brazil by ONKOS, which classifies indeterminate thyroid nodules with 97% sensitivity using the forefront of molecular biology and artificial intelligence knowledge. We will discuss the access and potential cost-effectiveness of this examination in the public and private sector.

Bartira Rossi Bergmann (LeishNano e UFRJ)
Title: Microparticulate implants for single dose treatment of chronic diseases such as Leishmaniasis
Abstract: Microparticulate subcutaneous implants for continuous drug delivery are an innovative technology for treating different types of diseases, particularly chronic ones. LeishNano is developing at UFRJ subcutaneous implants consisting of biodegradable microparticles for the single-dose treatment of cutaneous leishmaniasis (LC). Conventional treatment of 20-30 systemic injections with potentially toxic drugs causes serious side effects. LC is a neglected disease which WHO estimative of 4 million new cases / year in the world, most of which are uncomplicated (1-4 skin lesions) and could be treated locally. In addition to the obvious benefit to the patient, the cost of the technology can be compensated by reduced hospital costs, staffing, and distribution logistics by being given in a single dose. Once implanted, the platform could be used to treat other diseases, reducing the country's dependence on the importation of this type of medicine.


November 29th – Room Jequitibá

Thaís Cidália Gigonzac (SES-GO)
Title: Strategies for genetic research of individuals with Autism Spectrum Disorder (ASD) by the Public Health System in Goiás.
Abstract: Autism Spectrum Disorder (ASD) reflects an important demand on the health of children and adolescents that interferes with neuronal development, cognitive functions and behavioral changes, and it is fundamental to develop researches that contributes to the diagnosis and treatment of these individuals. The main objective of this study is to propose a genetic diagnosis strategy that will assist in the early intervention and health care of individuals with ASD by the Public Health System in Goiás. Patients with clinical indication of ASD referred by attending physicians to LageneSESGO will be evaluated. Chromosome Analysis by Microarray (CMA) will be performed to investigate structural genetic variations associated with clinical signs that may contribute to the intervention process. Complementarily, evidence on the genetic factors associated to the clinical profile may direct the work of the professionals involved in the rehabilitation of these individuals.

Marc Alexandre Gigonzac (SES-GO)
Title: Molecular diagnosis of the X-Fragile Syndrome: perspectives for the public health system in the central region of Brazil.
Abstract: X-Fragile Syndrome (FXS) is the most common cause of inherited intellectual disability and the second of genetic origin, with an estimated prevalence of 1/4000 men and 1/6000 women. The most common etiology is associated with a trinucleotide expansion of CGG sequences and hypermethylation of the promoter region of the FMR1 (Fragile-X Mental Retardation-1) gene, located in the Xq27.3 region. The symptoms occur from the lack of the Fragile X Mental Retardation Protein (FMRP), essential for dendrites growth and synaptic function. This syndrome is commonly underdiagnosed in children and adolescents due to the high phenotypic variability of patients and the need for a complex and high cost laboratory diagnosis. In the State of Goiás, a molecular diagnostic method for X-Fragile Syndrome was recently implemented through an optimized protocol using capillary electrophoresis. The correct molecular diagnosis of SXF is fundamental for the genetic counseling service, considering the direct correlation of the syndrome with expansions above 200 hypermethylated CGG repeats of FMR1, in addition to the risk of amplification of the region in offspring of individuals with pre-mutation. The use of molecular techniques associated with capillary electrophoresis in an automatic genetic analyzer demonstrated rapid and efficient investigation of CGG repeats in the FMR1 gene. Its inclusion in the public health service, besides universalizing access to genetic tests in Brazil, filling the gap between effective diagnosis and the technologies available until now, has supported families in clarifying the etiology and assessing the risk of recurrence.

Ester Nakamura (UFES)
Title: Non-invasive brain stimulation in the control of drug use in chemical dependence
Abstratc: Pre-frontal modulation induced by noninvasive cerebral stimulation, such as low intensity transcranial direct current (ECCT) stimulation, has been shown to be increasingly beneficial for many neurobehavioral disorders. We investigated the effects of ETCC on the dorsolateral prefrontal cortex (CPFdl) on the uncontrollable craving and / or relapse in drug usage in addicts. We have observed that the repetitive application (5 sessions) of the bilateral ETCC (cathode on the left CPFdl and the anode on the right CPFdl) reduces relapses for alcohol use in severe alcoholics and also the craving for crack/cocaine use in users of this substance. By increasing the number of sessions (10 sessions), craving was almost abolished at the end of treatment, notably crack/cocaine users. By LORETA analysis in both types of dependence, the ventral medial prefrontal cortex (CPFvm) was shown to be the region with the greatest change of activation in the P3 component (300-500 ms) under drug-related clues in those patients who maintained abstinence during and after treatment. The CPFvm is related to the control of the drug search, possibly by extinction of this behavior. Thus, repetitive bilateral ETCC (5 to 10 sessions) on CPFdl reduced relapse and craving for drug use and produced changes in pre-frontal activation, which may be of great importance in the control of drug use in addiction. These findings need to be confirmed in clinical trials involving larger samples of dependents to establish clinical use of ETCCs. In addition, a better understanding of this cognitive control over relapse and craving to use drugs involving prefrontal areas and their functional connectivity needs to be developed, and maintaining this cognitive control throughout life may require additional brain modulation techniques.

November 29th - Room Mandacaru

Emerson Lima Aredes (POLO BPM)
Title: Process management and clinical research.
Abstract: Organizations are process collections! And in clinical research this is no different. Everything that runs is part of a business process that involves various tasks, people, and organizations. The challenges of managing such processes in clinical research increase as the international market becomes more saturated and more research is attracted to ever-increasing levels of demand for Brazil. Therefore, the maturing of research units is fundamental and requires the understanding and improvement of processes, promoting best practices and improving quality. Process Management (BPM) is a managerial discipline that integrates strategies and objectives of an organization, contemplating expectations and needs of clients, through a focus on end-to-end processes in search of customer value addition and continuous organizational improvement. Thus, BPM is a key tool for the entire clinical research industry to understand and improve end-to-end processes, ie, regulation, approval, feasibility, ethics committee, contract, conducting visits together to participants, financial management, monitoring, adverse event management and protocol deviations, pharmacy, archive and post-study procedures. Everything is part of a great process and subprocesses and in this lecture we will discuss the challenges of clinical research in Brazil in the light of BPM and its consolidation in face of international requirements, the repercussion for the National Health System (SUS) and presentation of techniques and implementation cases in practice.

Marlan Geronimo (URCOM - SP)
Title: SANI system as a way of mobilizing financial resources.
Abstract: O SANI - Uma ferramenta para mobilização de recursos financeiros para compor a Saúde Municipal. Sistema Integrado de Apoio a Gestão da secretaria de Estado da Saúde tem como função básica a gestão de Processos e Documentos a ela relacionados. Para tanto atualmente possui funções que apoiam suas principais atribuições, como seguem: I – Gestão Orçamentária; II – Gestão Financeira; III – Gestão de Repasses; IV – Gestão de Convênios;

November 30th - Room Acácia

Paulo Roberto Slud Brofman (PUC-PR)
Title: Support and supply of stem cells in GMP conditions for the use in clinical and therapeutic trials
Abstract: The Cellular Technology Center of the Pontifical Catholic University of Paraná (CTC-PUCPR) is part of the National Network of Cellular Therapy (RNTC) and is in operation according to the regulations of the National Agency of Sanitary Surveillance (RDC 09/2011) and with VISA licensing to do so. We will present its facilities and organizational structure, its expertise in the support and production of adult stem cells (SC), autologous or allogeneic in GMP conditions, fresh or cryopreserved, with or without culture, with or without extensive manipulation for use in clinical research and/or therapy. The CTC-PUCPR has been producing SC for use in its own clinical trials and for numerous other research conducted in partnership with different institutions, in accordance with the objectives established by the National Network of Cellular Therapy. It also has an Experimental Laboratory of Cell Cultivation, Surgical Center for small and medium-sized animals, a Bank of Mesenchymal Cells approved by the ethics committie and a laboratory to control the quality of the cells produced by it.


November 30th – Sala Aroeira

Antonia Iracilda e Silva Viana (UFMA)     
Title: Development and evaluation of an app for high-risk pregnant women
Abstract: The health system has gradually advanced in the organization of care, but there is much to be done especially in relation to a certain part of the population that requires specialized attention, such as pregnant women. Health policy has also shown advances in the use and implementation of technologies. Although with the increasing technological advances in the health area it is necessary that this technology is used in favor of health care with the user being the main beneficiary. The objective of this project is the formulation and development of an app that can be used in a cell phone of any locality that encompasses the municipalities of the Region of Health Imperatriz by a High Risk pregnant woman who needs a proper orientation in the face of a clinic intercurrence in its pregnancy and that can be guaranteed through this application the access to an appropriate orientation, the contact with the doctor, transport and appropriate care in the Health Unit. Mobile technologies are already part of the daily life of health professionals. In this way, an experimental approach was carried out and na app was developed for assisting the follow-up of high-risk pregnant women. Basically, the system is connected to any computer in which the user has a login and password, at the Regional Maternal and Child Hospital - Imperatriz, where trained professionals can answer the questions sent by the pregnant women directly from the app chat. The system does not replace medical care. It encompasses a total of 17 municipalities served by the regional public health services, which have a precarious health system. With direct communication with the HRMI, it is possible to target the nearest appropriate service (the system has these data), in addition to the professional being able to access the pregnant woman's chart, analyzing potential risks and having the possibility of contacting competent authorities.

Ariadne Barbosa (UFV)
Title: Use of technology to promote integration in Health Surveillance in monitoring pregnant women infected with arboviruses
Abstract: The project, conducted by the research group VigSus, from the Post-Graduate Program in Nutrition Science of the Federal University of Viçosa - MG, aims to develop a technological tool that can optimize the field work of endemic agents and assist in the integration between health surveillance of small and medium-sized municipalities. The empirical study consisted in the analysis of the relationship between infection by Dengue and Zika arboviruses during the gestational period, its adverse results in concepts and the possible associations with health indicators.

Silvana Santos (UEPB)
Título: REDPB - Use of mobile technology to collect data on people with disabilities
Abstract: The REDPB - Epidemiological Picture of Deficiency in the State of Paraíba – is a software that allows the collection and management of data on people with disabilities to be used by community health agents. It consists in a system that can be used in a complementary way to the Basic Attention Information System (SISAB). The idea is to gather information that can explain the etiology of the disability and also the needs of the target public (people with disabilities). The development was funded by a public call from PPSUS/CNPq/PB.


November 30th – Room Buriti

Handerson Jorge Dourado Leite (IFB/BA)
Title: The Innovation Hub of the IFBA and the EMBRAPII financing model
Abstract: It will be presented the Salvador Innovation Hub (PIS) of the Federal Institute of Bahia as a unit accredited by the Brazilian Industrial Research and Innovation Company (EMBRAPII), focused on the development of innovative health technologies. It will also be described PIS structure, competencies and capacity, present the technological maturity level (TRL) analysis model and discuss the stages covered by the EMBRAPII funding. Finally, we will explain EMBRAPII funding rules and contract possibilities.

Ricardo Tolentino (Janssen Farmacêutica)
Title: Open Innovation - Modelo Johnson & Johnson
Abstract: To present the interested public how Johnson & Johnson, the world's largest healthcare company, has been developing its model of External Innovation, that is, the interaction model between the company and the external environment. J&J believes that innovation is the combination of people, ideas and technologies and these can come from anywhere on the globe. 


November 30th – Room Jequitibá

Rui Seabra Ferreira Junior (UNESP)
Title: Turning poison into medicine
Abstract: Animal toxins represent millions of years of evolution and have high affinity and specificity for different therapeutic targets. Our team specializes in translational medicine, experience gained with two bioproducts that are going into phase 3 of clinical trials and future registration. Following the same process, numerous other molecules are in our pipeline at different stages of development.

Fabiano Thompson (UFRJ)
Title: Biotechnological products of marine origin
Abstract: Infectious diseases represents a threat to human health, especially in the face of the proliferation of multiresistant microorganisms. Although fulfilling the promise of marine biotechnology as a source of environmental and biomedical applications remains a challenge, new opportunities have been opened up through the use of Brazilian marine biodiversity. Recent advances in marine biotechnology in Brazil, with the discovery of bioactive molecules (antibacterial, anti-viral, anti-biofilm) are promising examples. New technologies will be needed to extract the possibilities from marine biodiversity. Collaboration between the government, academic and private sectors will be crucial to create mechanisms for technology transfer and to promote the development of new marine biotechnology companies.

Mauro Sergio Pavão (UFRJ)
Title: Marine biotechnology and biomedical innovation - new marine sources of potent anti-metastatics
Abstract: Marine Biotechnology and Biomedicine have always been connected and have been expanding to consolidate the area of ​​Marine Biomedicine. Several marine biomedical research programs have been created and have been in consolidation in different parts of the world, aiming the discovery of new drugs from marine sources. In Brazil, Marine Biomedicine is moving towards consolidating itself through institutional efforts, both governmental and private, to establish multidisciplinary partnerships between academy groups, preclinical research centers, technological innovation centers and the pharmaceutical industry to connect research with translational preclinical and clinical research. We will describe the several stages of the research of a non-anticoagulant heparin analog, isolated in large quantities from a bivalve marine mollusc, grown in Brazil. The description includes structural characterization by nuclear magnetic resonance; the in vitro experiments demonstrating the mechanisms of anti-metastatic action involving the inhibition of P-selectin; the in vivo experiments in metastasis models, confirming the effect of inhibition of metastasis; and the evaluation of possible side effects in coagulation, cell viability, and the hypotensive effect. The results obtained guided the migration to preclinical tests aiming to solidify the proof of concept, to identify the most appropriate route of administration, and to assess pharmacology and toxicology safety.


November 30th – Room Mandacaru

Ricardo Abdalla (USP)
Title: RAMBO – Anatomy Morpho-biological recognition
Abstract: Protocol for obtaining surgical images for anatomomorphological recognition of normal human tissues and with alteration of abdominal disease

Ramon Salinas (UNICAMP)
Title: Technologies to meet the limitations of cervical cancer screening in Brazil
Abstract: For 7 years our team has been working on a technological solution, incorporating techniques of information systems, image processing in the detection of changes in the nuclei of cells that allows the prevention and diagnosis of cervical cancer in a fast and reliable way, improving the performance of the conventional Papanicolaou examination of geographically remote populations. The software used, called Vita, allows the delivery of Papanicolaou results in a record time of 180 minutes. In Vita software, image processing technologies are used, with a backing of more than 50 years of advances, offering the opportunity to use them at a low cost and great potential. A research was done on the optimization of information flow in the preventive diagnosis of cervical cancer by developing a methodology adapted to work in conjunction with the Brazilian Cervical Cancer Information System (SISCOLO). It is expected that at the end of Phase I implementation a low cost automatic image acquisition system will be developed that will optimize the capture and scanning of Papanicolau exams.

Liane Elizabeth Caldeira Lage (INPI)
Title: Current scenario and perspectives after Joint Ordinance 01/2017, INPI and ANVISA
Abstract: The end of the problem of competencies between the two institutions will be addressed, the operation of the backlog in relation to the patent applications of the health area in the INPI, and perspectives on the future.


November 30th – Room Pampa

Pedro Canisio Binsfeld (Executive Secretary of Conep)
Title: Recent advances by the National Research Commission - Conep
Abstract: When commemorating 20 years, Conep assumes that it needs to follow the evolution and modernization of the work process, in a dimension that allows it to present the solutions to the challenges established for the Commission. In this sense, Conep implements actions that promote advances in the system, among which, the following stand out: the speed in the analysis of protocols, creates a program of zero pendency; broadens the dialogue with related authorities and regulated sector, improves communication and transparency, initiates a process of debureaucratization and innovation, works on normative improvement and seeks insertion and international recognition as regulatory authority for research ethics. All these innovative actions are perceptible and put Conep in a new level, in line with the wishes of the research participants and include Brazil in the global scenario of innovative research and the country's interest in this strategic area.

registrado em:
Fim do conteúdo da página